Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Caplin Point Laboratories Limited

NSE: CAPLIPOINTPharmaceuticals

Share price

₹2,548.80

-3.79% close of 8 Oct 2026

Market cap ₹19,116 CrP/E 28.7

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 7 Oct 2026, the close above is 8 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

75

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹19,116 Cr

P/E ratio

28.7

P/B ratio

5.8

ROCE

24.2%

ROE

20.9%

Dividend yield

0.3%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹2,867.4052-week low ₹1,504.80

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 15.0% over the past year, and 26.8% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 30.8% to 34.8% over the last four years.

Whether it grew faster than its sector

It grew 26.8% a year against a sector median of 13.1% — 13.7 percentage points faster.

Room to re-rate, or risk of de-rating

At 28.7× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 23.4×, the 80th percentile of its own range.

Whether growth justifies the valuation

Priced at 1.5 times its growth rate, on earnings growth of 19%.

Profit growthPrice per ₹1 profitPer 1% growth
Caplin Point Laboratories Limited — this one19%/yr28.7×₹1.5
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 25 of 130 on returns, 12 of 127 on growth, 12 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 24.2% on capital, ahead of 81% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹1881 crore of cash from the business, spent ₹869 crore on plant and equipment, and returned ₹191 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 76 arrived as cash. Its cash comes back more slowly than it used to: it went from being waiting 165 days for its cash to waiting 199 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

8 of 9 checks clear · 89%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue rose 20% and profit rose 19% year over year.

Announced 12 Aug 2026 · Consolidated · Unaudited

Revenue

₹610 Cr

Revenue vs last year

+19.7%

Revenue vs last quarter

+1.7%

Net profit

₹179 Cr

Profit vs last year

+18.6%

Profit vs last quarter

+3.5%

Net margin

29.3%

EPS

₹23.27

Earnings call transcript · 12 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹19,116 Cr
Prev close
₹2,548.80
52w High
₹2,990
52w Low
₹1,500
Enterprise value
₹18,978 Cr
Beta
1.2
Price CAGR 1y
33.0%
Price CAGR 3y
35.0%
Price CAGR 5y
25.0%
Price CAGR 10y
25.0%

Ratios

Return on assets
16.1%
PEG ratio
1.5
P/E ratio
28.7
P/B ratio
5.8
EV / EBITDA
25.6
Industry P/E
38.0
ROCE
24.2%
ROCE 5y average
26.0%
ROE
20.9%
Debt / Equity
0.1
Interest coverage
804.0
Dividend yield
0.3%
ROE 3y average
22.0%
ROE last year
21.0%

Annual P&L

Annual revenue
₹2,187 Cr
Annual profit
₹650 Cr
Operating margin
35.0%
Net profit margin
29.7%
EBITDA margin
35.0%
Sales growth 3y
14.2%
Sales growth 5y
15.6%
Profit growth 3y
19.0%
Profit growth 5y
21.0%
EPS
₹84.4
Sales growth TTM
15.0%
Profit growth TTM
18.0%
Dividend payout
9.0%

Quarter P&L

Sales latest quarter
₹610 Cr
Profit latest quarter
₹179 Cr
YoY quarterly sales growth
19.6%
YoY quarterly profit growth
18.5%
OPM latest quarter
35.0%

Balance Sheet

Book Value
₹449
Face Value
₹2.0
Total debt
₹221 Cr
Total cash
₹621 Cr
Borrowings
₹221 Cr
Reserves / Equity
223.7

Cash Flow

Operating cash flow
₹523 Cr
Free cash flow
₹275 Cr
FCF yield
1.4%
Net cash flow
-₹105 Cr

Shareholding

Promoter holding
70.6%
FII holding
5.8%
DII holding
2.5%
Public holding
21.2%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.94,28,0570.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.52,54,6650.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.31,79,1640.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,14,9630.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.31,10,6990.10362.1125.52,026.329.117.8
Cipla1,327.2029.91,06,9970.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.71,03,8760.04574.129.64,030.612.913.5
Caplin Point Lab2,649.1030.320,1400.30179.115.8610.419.624.2
Median417.9034.42,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales395410436453459483493502510534543600610
Expenses269273293308307318331334332345353396397
Material Cost61749289102107
Change in Inventories1.598.23-3.72-2.10-66-58
Purchases of Stock-in-Trade139114122128209196
Employee Cost474347505354
Other Expenses879487889898
Operating Profit127137142145152165162168178189190204213
OPM %32343332333433333535353435
Other Income12211717192131262330342834
Exceptional items (within Other Income)000000
Interest0000000000000
Depreciation11121416161716171618191922
Profit before tax127146145146154168177177184201204213225
Tax %18201817192221181820191920
Net Profit104116120121125131140145151160166173179
EPS in Rs14151516161718192020222223
Diluted EPS in Rs192020222223

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemJun 2015Mar 2016 9mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales2522394025406498631,0611,2691,4671,6941,9372,1872,287
Expenses1921752763454176037328741,0251,1421,2871,4221,491
Material Cost248357
Change in Inventories-53-64
Purchases of Stock-in-Trade576572
Employee Cost178199
Other Expenses342362
Operating Profit6064125195232260329395442552651765797
OPM %24273136363031313033343535
Other Income34101319412338556692111126
Exceptional items (within Other Income)00.04
Interest10111021110.610.871
Depreciation871319233237474553667378
Profit before tax5360121188227269314386451564677803844
Tax %232421232220202016182019
Net Profit414696145177215251308377461541650678
EPS in Rs5.436.051319232832405060718488
Diluted EPS in Rs7084
Dividend Payout %18201210999109889

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
25%
5 years
16%
3 years
14%
TTM
15%

Compounded profit growth

10 years
30%
5 years
21%
3 years
19%
TTM
18%

Stock price CAGR

10 years
25%
5 years
25%
3 years
35%
1 year
33%

Return on equity

10 years
25%
5 years
23%
3 years
22%
Last year
21%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemJun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital151515151515151515151515
Reserves781132103495828589541,2521,6492,0842,6193,355
Borrowings221136113235219222219222221
Other Liabilities134137133136109139159250305380352446
Minority Interest3644
Total Liabilities2292673585007431,1261,3641,7362,1912,6983,2084,038
Fixed Assets113144152169227272305287280453546580
CWIP31031510201418221117144234
Investments00174770611189281376590859
Other Assets851221862694367721,0331,3431,4101,7531,9282,365
Total Assets2292673585007431,1261,3641,7362,1912,6983,2114,045

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemJun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity504268668345269337271318432523
Cash from Investing Activity-23-6-36-69-100-54-30-377-216-319-333-582
Cash from Financing Activity-9-14-7-129080-24-41-28-38-38-46
Net Cash Flow192325-147370215-8127-3961-105
Free Cash Flow2434431818-3219524678173240275

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemJun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days81230859097969198117119138
Inventory Days3757444447210139149159183159181
Days Payable11216815514476576810284116103125
Cash Conversion Cycle-67-99-81-1661251166138173184175194
Working Capital Days-128-114-2947104167145165144166174199
ROCE %686268634533282826262624

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters717171717171717171717171
FIIs3.092.843.333.383.714.865.736.166.516.586.155.76
DIIs0.210.431.081.491.832.1122.222.102.052.142.49
Public262625252422222121212121
No. of Shareholders78,06879,43881,40980,41196,12392,70296,38794,16993,75393,70593,89694,385

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +25.8% (₹2,026.10 → ₹2,548.80)Brick size ₹111.97 (fixed)Bricks 17
₹2,000₹2,549Dec '25Jun '26
Price moved up one brickPrice moved down one brickLast close ₹2,548.80 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

52,08,383inr

2026-03-31

News

News and filings about Caplin Point Laboratories Limited. Open one to see why it matters.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Active pharmaceutical ingredients (APIs), intermediates & key starting materials (KSMs)
  • Medical disposables
  • Outsourced / purchased finished formulations (stock-in-trade)
  • Packing materials (glass vials, plastics)
  • Solvents

Sells to

  • Own Latin America / Francophone Africa front-end (branded-generic wholesale, retail pharmacies & government institutional tenders via Caplin's own LatAm subsidiaries) · finished pharmaceutical formulations (injectables, softgels, orals, ophthalmics, topicals)

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE475E01026

Business segments

  • Rest of the World · 79%
  • USA · 21%

Plants

  • CP-I (Caplin Point Laboratories Unit-I)
  • CP-IV (Caplin Steriles Ltd)
  • CP-LL1 (Caplin Point Laboratories LL-1)
  • CP-LL2 (Caplin Point Laboratories LL-2)
  • CP-X API plant
  • Caplin One Labs Ltd (COL) oncology unit
  • Thervoy SIPCOT oncology & general-category API facility

News impact

Big market events that reach Caplin Point Laboratories Limited, and how the effect spreads.

Who it hits first

  • Sterile-injectable makers (Gland, Aurobindo, Lupin, Caplin, Shilpa) face new licensing layer
  • Small job-work sterile units face consolidation pressure
  • CDSCO capacity becomes the approval bottleneck

Who may gain

  • Large compliant players gain share as small units exit
  • Testing and validation service firms gain business

Along the supply chain

Downstream

Hospitals pay slightly more for assured-quality injectables.

Upstream

API and vial suppliers see steadier demand from compliant makers.

Where demand moves

Business

Plants undergo central audits; documentation and QA headcount rise; approvals add months to greenfield timelines.

Capital

Money favours large, audit-ready pharma over small sterile job-workers.

How it spreads across sectors

Healthcare

injectable compliance cost rises; consolidation favours leaders

When it plays out

Immediate

Injectable stocks soften on cost headlines.

Medium term

Cleaner industry commands better US/EU pricing power.

Short term

Watch draft rules, timelines and grandfathering clauses.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

18 Sep 2026unspecified₹4
29 May 2026interim₹4
12 Sep 2025unspecified₹3
30 May 2025interim₹3
23 Sep 2024unspecified₹2.5
31 May 2024interim₹2.5
14 Sep 2023unspecified₹2.5
9 Jun 2023interim₹2

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.